Rheumatology

Journal Club ft. NEJM publications

Questions discussed in this category

At what point do you consider a patient to have relapsing PMR?

How much cumulative prednisone exposure do you tolerate and how many attempts at tapering will you pursue before considering addition of a steroid spa...

4 Answers available

How will you approach tapering sarilumab in patients with PMR in remission?

After what interval of sustained remission will you attempt to taper, and will you do so by first widening the dosing interval?

2 Answers available

Would you avoid combining JAK inhibitors with IVIG given the risk of thromboembolism?

4 Answers available

How will you approach drug sequencing in patients with PMR given the SAPHYR data?

Will you initiate sarilumab as a first steroid sparing agent or will you still pursue a DMARD such as methotrexate before initiating sarilumab? To wha...

2 Answers available

How will you adjust your approach to steroid taper in patients with PMR also on sarilumab?

2 Answers available

What baseline and ongoing testing do you recommend for patients with PMR who are going to be on a prolonged steroid taper?

Do you universally perform baseline DEXA and Hgb A1C? How often are you obtaining routine labs?

2 Answers available

How do you recommend tapering IVIG in patients whose inflammatory myositis has achieved remission?

4 Answers available

Which myositis patients are good candidates for IVIG?

3 Answers available

How long can you treat dermatomyositis with IVIG?

3 Answers available

How do you approach CV risk assessment in RA patients when RA itself is associated with some degree of increased CV risk at baseline?

Recent articles regarding the use of JAK-Inhibition in RA have suggested to avoid in patients with increased CV risk. However, RA itself is cons...

2 Answers available

Would you recommend that a patient with stable coronary artery disease and well-controlled RA on a JAK inhibitor continue on their current therapy?

2 Answers available

Do you still plan to offer tofacitinib to RA patients over 65 if they have one or more additional CV risk factors?

2 Answers available

How do you counsel patients regarding the cardiovascular and cancer risks associated with tofacitinib?

2 Answers available

Should the use of avacopan be limited to those patients at increased risk of steroid toxicity given the anticipated high cost of this medication?

ADVOCATE trial

1 Answer available

How should the results of the ADVOCATE trial be applied in AAV patients who receive rituximab induction and maintenance therapy?

In the ADVOCATE trial, patients were not re-dosed with rituximab.

1 Answer available

Are there particular subsets of AAV patients in which avacopan is more effective?

E.g., MPO vs PR3, newly diagnosed vs relapsed, renal involvement. Acknowledge that the ADVOCATE study was not powered to detect these differences, but...

1 Answer available